Why Half of GLP-1 Users Quit — The Real Discontinuation Data

What They Found

This study examined real-world discontinuation patterns for GLP-1 receptor agonists and tirzepatide, tracking both the reasons patients stop and what happens to their health outcomes afterward. The research provides concrete data on discontinuation rates and the primary factors driving treatment cessation.

Why It Matters

GLP-1 receptor agonists like semaglutide and liraglutide, along with the dual agonist tirzepatide, have revolutionized weight management and diabetes control. But clinic data tells us discontinuation is common — and until now, we've had limited systematic data on why patients quit and what the consequences are.

The mechanisms matter here. GLP-1 receptor agonists work by slowing gastric emptying, enhancing glucose-dependent insulin secretion, and acting on hypothalamic appetite centers. These effects are dose-dependent and reversible. When patients discontinue, we expect rapid return of gastric motility, loss of central appetite suppression, and reversal of metabolic benefits within weeks to months.

Tirzepatide adds GIP receptor agonism to the mix, potentially creating different discontinuation patterns due to its enhanced efficacy but also potentially different side effect profiles. The dual mechanism may influence both tolerance and durability of effects.

What I'd Watch For

Real-world discontinuation studies are notoriously difficult to interpret because they capture heterogeneous patient populations with varying motivations, insurance coverage issues, and clinical contexts. The key question is whether discontinuations were due to intolerable side effects, achievement of goals, cost barriers, or loss of efficacy.

We need to see the methodology clearly — how long were patients followed, what constituted "discontinuation," and whether the consequences measured included weight regain kinetics, metabolic parameter changes, and cardiovascular outcomes. Without this granular data, we can't distinguish between informed treatment cycling and problematic adherence failures.

Bottom Line

Discontinuation data is clinically critical for setting patient expectations and designing sustainable protocols. If the primary drivers are manageable (dosing, timing, food interactions), that changes the conversation completely versus discontinuation due to fundamental intolerance. I'd use these findings to refine patient selection and counseling, but only after seeing the full methodology and results.